Clinical trials: Prostate Cancer, Castration Resistant
Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
This phase II trial studies the effect of erdafitinib in treating patients with prostate cancer that grows and continues to spread despite the surgical removal of the testes or drugs to block androgen production…
- Conditions
- Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma
- Trial name
- NCT04754425
- Testing
- Biopsy, Biospecimen Collection, Erdafitinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
This randomized phase II trial studies how well olaparib with or without cediranib works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic).
- Conditions
- Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Carcinoma
- Trial name
- NCT02893917
- Testing
- Cediranib, Olaparib
- Where
- 16 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer
The purpose of this international, phase 2, open-label, response rate study of talazoparib is to assess the efficacy and safety of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer (CRPC)…
- Trial name
- NCT03148795
- Testing
- Talazoparib
- Where
- 120 sites in United States, Australia and 12 more
- Volunteers
- 128 people
- Sponsor
- Pfizer
Prostatic Neoplasms, Castration-Resistant, Drug Therapy, Combination
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
This is a phase Ib/II clinical study of TQB3616 capsules in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer, to determine the dose for further clinical studies…
- Trial name
- NCT05156450
- Testing
- TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone
- Where
- China
- Volunteers
- 30 people
- Sponsor
- West China Hospital
Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination…
- Conditions
- Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Trial name
- KAT6 (NCT04606446)
- Testing
- PF-07248144, Fulvestrant, Letrozole
- Where
- 43 sites in United States, Australia and 3 more
- Volunteers
- 320 people
- Sponsor
- Pfizer
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC)
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1…
- Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS)
- Trial name
- NCT02649790
- Testing
- KPT-8602, ASTX727, Dexamethasone
- Where
- 46 sites in United States, Canada and 3 more
- Volunteers
- 277 people
- Sponsor
- Karyopharm Therapeutics Inc
Prostate Cancer
Integrated 18F-labelled PSMA Project
There are several new therapies available to treat men with advanced prostate cancer; however, the decision making tools needed to determine the best treatment for these patients are noticeably absent.
- Trial name
- NCT02691169
- Testing
- 18F-DCFPyL
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Metastatic Castration-resistant Prostate Cancer
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
This is a single arm Phase Ib/II, open label, safety, pharmacokinetic and efficacy clinical study in adult patients with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT04253262
- Testing
- Rucaparib, Copanlisib
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Brown University
Castration-resistant Prostate Cancer, Metastatic Breast Cancer
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
The purpose of this first multi-dose study in cancer patients is to determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D), characterize the safety, tolerability and pharmacokinetics profile.
- Conditions
- Castration-resistant Prostate Cancer, Metastatic Breast Cancer, Uterine Leiomyoma
- Trial name
- NCT01338831
- Testing
- LFA102
- Where
- 9 sites in United States, Belgium and 2 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer
The purpose of this study is to assess the safety and efficacy in Korea or Taiwan of oral abiraterone acetate and oral prednisolone in men with metastatic-castration resistant prostate cancer (mCRPC) and with disease progression…
- Trial name
- NCT01685983
- Testing
- Abiraterone acetate, Prednisolone
- Where
- 8 sites in South Korea, Taiwan
- Volunteers
- 82 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer Metastatic
HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer
This is a first-in-human Phase 1/2, multinational, multicenter, open-label study of HB-302/HB-301 alternating 2-vector therapy in participants with metastatic castration-resistant prostate cancer (mCRPC) comprising 2 phases: a…
- Trial name
- NCT05553639
- Testing
- HB-302/HB-301 Alternating 2-Vector Therapy
- Where
- 10 sites in United States
- Volunteers
- 12 people
- Sponsor
- Hookipa Biotech GmbH
mCRPC (Metastatic Castration-resistant Prostate Cancer), Advanced Malignant Solid Tumor
A Study of MHB048C in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase I/II study of MHB048C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of…
- Trial name
- NCT07192120
- Testing
- MHB048C for Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
This randomized, placebo-controlled phase III trial is evaluating the benefit of rucaparib and enzalutamide combination therapy versus enzalutamide alone for the treatment of men with prostate cancer that has spread to other…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- CASPAR (NCT04455750)
- Testing
- Enzalutamide, Rucaparib camsylate, Leuprolide Acetate
- Where
- 414 sites in United States
- Volunteers
- 61 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Neoplasms
Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer
This Phase I, open-label, dose-finding, multicenter study is designed to determine the recommended Phase II dose (RP2D) for the combination of an orally administered Phosphatidylinositol-4,5-bisphosphate 3-kinase beta (PI3K-beta)…
- Trial name
- NCT02215096
- Testing
- GSK2636771, Enzalutamide
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer Metastatic to Bone
Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy
Radium-223 chloride is an alpha-emitting radiopharmaceutical with proven survival benefit in patients with castration-resistant prostate cancer metastatic to bone.
- Trial name
- RaRe (NCT03458559)
- Testing
- Radium-223 chloride, Rhenium-188-HEDP
- Where
- Netherlands
- Volunteers
- 402 people
- Sponsor
- Amsterdam UMC, location VUmc
Metastatic Castration-resistant Prostate Cancer
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant…
- Trial name
- NCT03732820
- Testing
- olaparib, abiraterone acetate
- Where
- 132 sites in United States, Australia and 15 more
- Volunteers
- 895 people
- Sponsor
- AstraZeneca
Metastatic Castration-Resistant Prostate Cancer
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer
This phase 2 randomised clinical trial will investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy.
- Trial name
- ENZA-p (NCT04419402)
- Testing
- Lu-PSMA, Enzalutamide
- Where
- 15 sites in Australia
- Volunteers
- 162 people
- Sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Metastatic Castration-resistant Prostate Cancer
Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)
The SPECTacular study will enroll patients who are already undergoing a FDA approved PSMA-targeted Radioligand treatment cycle. During each treatment cycle, patients will receive 5 additional SPECT/CT scans to investigate the…
- Trial name
- SPECTacular (NCT05823402)
- Testing
- SPECT/CT
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- BAMF Health
Prostate Cancer Metastatic Castration-Resistant
External Beam and Radioligand Radiotherapy for mCRPC
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy with Lutetium-177 (¹⁷⁷Lu-PSMA) is an established treatment for metastatic prostate cancer.
- Trial name
- ARREST (NCT07354594)
- Testing
- External Beam Radiotherapy Delivered Between Cycles of Radioligand Radiotherapy, Standard of care 177Lutetium-PSMA
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
This is a Phase 1b/2 study evaluating FOR46 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) after prior progression on abiraterone.
- Trial name
- NCT05011188
- Testing
- FOR46, Enzalutamide, Pegfilgrastim
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Rahul Aggarwal
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.